Quarterly ResultNov 12, 2026, 04:24 PM
Lineage Cell Therapeutics Reports Q3 2026 Net Income of $4.23M vs. $29.78M Loss
AI Summary
Lineage Cell Therapeutics, Inc. reported a net income of $4.232 million for the third quarter of 2026, a substantial turnaround from a net loss of $29.781 million in the same period of 2025. However, total revenues decreased to $1.434 million from $3.681 million year-over-year, while operating expenses rose to $8.748 million. The company's cash position decreased, and total liabilities saw a significant reduction, primarily due to a decrease in warrant liabilities.
Key Highlights
- Lineage Cell Therapeutics reported a net income of $4.232 million for the three months ended September 30, 2026, a significant improvement from a net loss of $29.781 million in the prior year period.
- Total revenues for the three months ended September 30, 2026, were $1.434 million, down from $3.681 million in the same period last year.
- Operating expenses for the three months ended September 30, 2026, were $8.748 million, an increase from $7.467 million in the prior year period.
- Cash and cash equivalents decreased to $26.499 million as of September 30, 2026, from $40.791 million as of December 31, 2025.
- Total assets decreased to $100.110 million as of September 30, 2026, from $112.584 million as of December 31, 2025.
- Total liabilities decreased significantly to $34.167 million as of September 30, 2026, from $69.238 million as of December 31, 2025, largely due to a decrease in warrant liabilities.
Price Impact
More from LCTX